English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.
Tag: prostate cancer
Research uncovers alternate mechanism for producing key protein in metastatic prostate cancer
In the Nature Cancer study, researchers led by Dana-Farber’s Himisha Beltran, MD, and Martin Bakht, PhD, found that PSMA expression is lower in liver metastases than in other parts of the body, regardless of expression of the androgen receptor. They also found that some tumors that test negative for the AR do express PSMA and that some AR-positive tumors don’t – which led them to look for a control mechanism that doesn’t involve the AR. Their search revealed that the HOXB13 protein as a key regulator of PSMA.
Novel Immunotherapy Agent Safe, Shows Promise Against High-Risk Prostate Cancers
A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.
More U.S. Prostate Cancer Patients Choosing Active Surveillance
The number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable-intermediate-risk cancers, according to a study published today in JAMA Internal Medicine.
ENZAMET shows promise as prostate cancer treatment
A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.
Scientists Pioneer Research to Harness Power of Machine Learning in Prostate Cancer Imaging
Researchers at Sylvester Comprehensive Cancer Center and the Desai Sethi Urology Institute are pioneering research to harness machine learning for the diagnosis and prognosis of prostate cancer, using magnetic resonance imaging (MRI).
Delaying treatment for localised prostate cancer does not increase mortality risk, trial shows
Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind today.
Mediterranean diet the best prevention against prostate cancer
New research from the University of South Australia shows that men who stick to a predominantly Mediterranean diet are less likely to be diagnosed with prostate cancer. This diet also improves their chances of recovery if they have prostate cancer and are undergoing radiation treatment.
UChicago Medicine-led team selected for the 2022 Michael & Lori Milken Family Foundation-PCF Challenge Award to develop novel immunotherapy approaches in advanced prostate cancer
The Prostate Cancer Foundation (PCF) has awarded a $1 million grant to a renowned specialist at the University of Chicago Medicine Comprehensive Cancer Center.
Newly identified personalized immunotherapy combination treats an aggressive form of advanced prostate cancer
A combination treatment that targets the immune system helps treat aggressive prostate cancers that don’t respond to conventional therapies.
New treatment approach for prostate cancer could stop resistance in its tracks
For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme. The findings could help address the growing threat of prostate cancer resistance and could also lead to improved treatments for other cancers.
American College of Surgeons Experts Available to Speak on Concerning Trends in Advanced Prostate Cancer
CHICAGO: After two decades of decline, rates of advanced prostate cancer are on the rise, causing concern among physicians and healthcare organizations around the nation. American College of Surgeons (ACS) experts are available to help the media and public understand…
Hackensack Meridian JFK University Medical Center Offers Innovative PSMA PET Imaging Test to Aid in Diagnosis of Prostate Cancer
“The availability of the PYLARIFY test at JFK University Medical Center means patients with prostate cancer no longer need to travel to obtain PSMA-targeted PET imaging. They can get this innovative technology close to home,” said Amie Thornton, president, chief hospital executive, JFK University Medical Center.
‘Urology on the Beach’ Conference Highlights Advances in Research and Patient Care
From urologic cancers to female urology to male infertility to kidney stones and sexual health, top urologists from throughout the nation shared their insights and practical tips at “Urology on the Beach,” a conference hosted January 13-15 by the Desai Sethi Urology Institute at the University of Miami Miller School of Medicine.
Structural insights reveal how SPOP protein contributes to cancer
Scientists at St. Jude Children’s Research Hospital captured the 3D structure of SPOP, revealing how mutations in previously unappreciated regions fuel cancer.
Moffitt Researchers Develop Tool to Measure Patient Health and Well-Being after Radionuclide Therapy
Moffitt Cancer Center researchers have developed a tool to determine how a new class of prostate cancer therapies called radionuclide therapy (RNT) impacts patient-reported outcomes with the goal of using this information to guide treatment and improve quality of care. Their findings have been published in The Journal of Nuclear Medicine.
Prostate cancer experts available to discuss new ACS data and need to reconsider screening guidelines
A new American Cancer Society report points to a rise in advanced prostate cancer cases, the first increase seen in 20 years. Doctors are available to discuss this alarming trend and the need to revisit national PSA screening guidelines. Dr.…
MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer
For men who undergo radiotherapy for localized prostate cancer, the precise targeting capabilities of MRI guidance resulted in fewer toxicities and better quality of life according to new research from UCLA Jonsson Comprehensive Cancer Center.
American Cancer Society Releases Latest Cancer Statistics, Launches Initiative to Address Prostate Cancer Resurgence and Disparities
Today, the American Cancer Society released Cancer Statistics, 2023, the organization’s annual report on cancer facts and trends. According to the report, overall cancer mortality has dropped 33% since 1991, averting an estimated 3.8 million cancer deaths. Based on ACS data, in 2023 there are projected to be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States.
Study Finds Providers Use Prostate Cancer Screening Tests, Even When They Provide Little Value to Patients
Prostate cancer is the second-leading cause of cancer death in men with more than 34,000 deaths in the U.S. each year, according to the American Cancer Society. But guidelines for prostate cancer screening are continually shifting, leading to uncertainty among patients and providers on when and if screening tests should be ordered. In a new study from Wake Forest University School of Medicine, researchers recently examined prostate screening testing among primary care providers and found that the tests are frequently used, even when they provide little value to patients.
New Study Shows Western Region has Highest Prostate Cancer Mortality Among White Men in U.S.; Black Men Face Highest Prostate Cancer Mortality Overall
New findings led by researchers at the American Cancer Society show the highest mortality rates for prostate cancer in White men were found in the Western region of the United States, including California, despite low incidence rates.
Scientists identify multiple cell types that may contribute to treatment resistance in prostate cancer
Researchers have characterised prostate cancer cell dynamics at a single-cell resolution across the timespan of the disease – from its beginning to the point of androgen independence, where the tumour no longer responds to hormone deprivation therapy.
Family History, Gene Variants Put Black Men at Risk for Early Prostate Cancer
A family history of cancer and genetic variants that might be inherited appear to be important risk factors for Black men diagnosed with early-onset prostate cancer, a study involving Duke Health researchers has found.
Drug triggers immune cells to attack prostate cancer
A single drug compound simultaneously attacks hard-to-treat prostate cancer on several fronts, according to a new study in mice and human cells.
Study Reveals Pathways for Aggressive Prostate Cancer Subtype
The findings, which are the result of single-cell RNA-sequencing, were published in Nature Communications. The research was conducted in the lab of Paula Hurley, PhD, associate professor of Medicine and Urology. The researchers observed an interplay between the inherent properties of cancer cells and microenvironmental factors that contribute to this aggressive subtype of prostate cancer.
CANCER RESEARCH INSTITUTE TO HOST ANNUAL VIRTUAL IMMUNOTHERAPY PATIENT SUMMIT ON NOVEMBER 11-12, 2022
Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.
Metastasis-directed radiation therapy plus hormone therapy improves progression-free survival for men with advanced prostate cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival (PFS) in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.
Radiation-hormone therapy combination may slow growth of oligometastatic prostate cancer
A new study offers a new option to patients with oligometastatic prostate cancer who want relief from hormone therapy without compromising the risk of their disease spreading. In the study, patients who received radiation in addition to intermittent hormone therapy lived longer without their disease progressing, and they were able to take longer breaks from the drug treatments. Results of the phase II trial (EXTEND; NCT03599765) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Lower prostate cancer screening rates associated with subsequent increase in advanced cancers
In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.
Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer
A new randomized study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy.
Sexual side effects of cancer treatment often unaddressed with female patients
A new study finds that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs.
New analysis led by UCLA Jonsson Comprehensive Cancer Center finds timing androgen-deprivation therapy with radiation therapy improves outcomes in localized prostate cancer
In a large analysis of over 7,000 men treated internationally across 12 randomized trials, study shows that it is almost universally optimal for men to begin androgen deprivation therapy when starting radiation.
Study Offers New Hope for Treatment-Resistant Prostate Cancer
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that they can circumvent a key mechanism in castration-resistant prostate cancer (CRPC) and possibly make immunotherapies more effective. By infusing nitric oxide (NO) into animal models, the team shrank tumors and paved the way for potential combination therapies. The study was published in Nature Cell Death & Disease.
Desai Sethi Urology Institute Draws Renowned Urologists, Researchers to Inaugural ‘Urology on the Beach’ Meeting, January 2023
The Desai Sethi Urology Institute at the University of Miami Miller School of Medicine will be hosting urology clinicians and scientists from today’s most prominent academic centers at the institute’s inaugural in-person “Urology on the Beach” meeting, January 13 to 15, 2023, at the Fontainebleau Hotel in Miami Beach.
Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in San Antonio
The American Society for Radiation Oncology (ASTRO) announced today the 10 studies that will be highlighted in the 2022 ASTRO Annual Meeting press program. Researchers will discuss their findings in two news briefings to be held October 24 and 25 in the Henry B. Gonzalez Convention Center in San Antonio and via live webcast. Reporters can register for the meeting at astro.org/annualmeetingpress.
More Thank 100 Men Get Screened for Prostate Cancer for Free in Hackensack
More good news on top of the Giants Winning this past Sunday! More than 100 New Jersey men are now better informed about their health thanks to former NFL great, Harry Carson, who attended Hackensack Meridian Health’s first annual Men’s…
Men’s Health Day Targets Those at High Risk for Prostate Cancer – Including African Americans
Join NY Giants great Harry Carson and Hackensack Meridian Health, Screenings for Prostate Cancer, High Blood Pressure, Diabetes, Asthma & Lung Disease and More
Sylvester Game Changer Vehicle Among First in Nation to Offer Mobile Prostate Cancer Screening
Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game Changer vehicles, which bring health education and free screenings for many cancer types to South Florida communities in need, are for the first time offering prostate-specific antigen (PSA) screening for prostate cancer.
Mayo Clinic researchers identify drug resistance factors for advanced prostate cancer
In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.
Genomic Testing Can Identify African American Prostate Cancer Patients Who Have High-Risk Disease
Moffitt Cancer Center has conducted the first prospective study to investigate genomic biomarkers associated with aggressive disease in African American men with prostate cancer. The study results were published in the Journal of the National Cancer Institute.
Study suggests commonly used prostate cancer treatment rewires engine of prostate tumors
A new study from the University of Michigan Rogel Cancer Center suggests androgen receptor inhibitors can fundamentally rewire and reshape how prostate tumors function, and in certain cases even make them more aggressive. These findings will be published in Nature Communications on Sept. 15.
Betamethasone could improve outcomes for prostate cancer radiation therapy
A new study published by University of Kentucky Markey Cancer Center researchers suggests that the common steroid betamethasone could be used to reduce unwanted side effects of radiation treatments for prostate cancer.
Prostate Cancer Cases Risk Being Detected Too Late Due to Misleading Focus on Urinary Problems
Men with early, curable stages of prostate cancer are missing opportunities to have their cancer detected because national guidelines and media health campaigns focus on urinary symptoms despite a lack of scientific evidence, say experts at the University of Cambridge.
Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease
Hormone therapy for prostate cancer increases the risk of cardiovascular disease-related death especially in older men, according to a population study involving more than 13,000 patients.
MD Anderson Research Highlights for July 27, 2022
Clinical advances include treating hematologic cancers with effective targeted therapies, circulating tumor DNA as a biomarker for recurrence with colorectal liver metastases, and using magnetic resonance imaging (MRI) to guide surgical decisions for patients with lateral pelvic lymph node metastases in rectal cancer. Laboratory findings offer new understanding of the pancreatic cancer immune microenvironment, melanoma cell states, TP53 mutation status in acute myeloid leukemia (AML), and potential targets for metastatic prostate cancer and GNAS-mutant colorectal cancer.
Defining the Landscape of Prostate Cancer Treatment
Smilow Cancer Hospital is now offering a new surgical option for prostate cancer treatment unavailable elsewhere in Connecticut, and still rare throughout the United States. The beneficiaries are men in need of a prostatectomy, a procedure in which the prostate is partially or completely removed to eradicate localized cancer.
Gut Microbes Differ in Men with Prostate Cancer
Researchers have found a significant difference in the gut microbiota of men with prostate cancer, compared with those who have benign biopsies.
Moffitt Study Shows Adaptive Therapy Improves Outcomes, Reduces Care Costs for Prostate Cancer Patients
Researchers in Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center are thinking outside the box and studying an alternative approach called adaptive therapy that is based on evolutionary principles and mathematical modeling. In a new article in eLife, the researchers report updated results from a pilot clinical trial evaluating an adaptive therapy approach using the drug abiraterone to treat patients with metastatic castrate-resistant prostate cancer.
Scientists blend AI, 3D tissue imaging to identify aggressive prostate cancer
Researchers at Case Western Reserve University and the University of Washington expect to gain valuable new insights into highly aggressive prostate cancer by combining Artificial Intelligence (AI)-powered diagnostic imaging with three-dimensional (3D) tissue imaging.
The Lancet Publishes Sylvester-Led Study Defining New Standard of Care for Prostate Cancer Recurrence After Prostatectomy
Adding short-term hormone therapy and pelvic lymph node radiotherapy to standard of care prostatectomy surgical bed treatment benefits prostate cancer patients whose prostate-specific antigen (PSA) levels are rising post prostatectomy, according to an international study led by Alan Pollack, M.D.,…